BridgeMD
Tests treatment safety and results for Respiratory Syncytial Virus (RSV)
Official title A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.
ClinicalTrials.gov ID: NCT07543380
What this study is testing
What is RSVpreF?
RSVpreF is an investigational medicine, given as an once-daily, being studied as a potential treatment for respiratory syncytial virus (rsv).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of the study is to learn about the immune response after a RSVpreF vaccination. This study is being conducted in Japan.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 59
You may be able to join if
- Underlying health condition(s) that can put the participant at an increased risk of severe RSV/complications including chronic lung , heart, kidney...
You likely can't join if
- Received any kind of RSV vaccine before participating in this study
- Determined as not eligible by the investigator based on the participant's past and present health condition(s), medication(s) and treatment(s) Please...
The study team makes the final eligibility decision.
Where it's taking place
- Tsuchiura, Ibaraki, Japan
- Chuo-ku, Tokyo, Japan
- Fukuoka, Japan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 59 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Tsuchiura, Ibaraki, Japan; Chuo-ku, Tokyo, Japan; Fukuoka, Japan. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.